TrialJCO global oncology2022

Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study.

Ruben D Kowalyszyn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.